ArticleAnalytical and bioanalytical chemistry2026
Comprehensive distribution analysis of cyclosporin A on mice tissues applying mass spectrometry imaging.
Article in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Peptide drugs are playing an indispensable role in clinical therapy, but may exhibit significant dose-dependent toxicities, as observed in polymyxin antibiotics and cyclosporin A (CsA) itself. The spatial distribution of these drugs and their metabolites is crucial for understanding the tissue-specific pharmacokinetics. The goal of our study was to develop and evaluate a mass spectrometry imaging (MSI) workflow using atmospheric pressure matrix-assisted laser desorption and ionization mass spectrometry imaging (AP-MALDI-MSI) with the iMScope QT system for the detection and spatial visualization of CsA in mice organs. Based on the CsA signal sensitivity and consistent detection of the CsA standard in our optimized experimental condition, we chose iMScope QT for subsequent in vivo MSI experiments. Following intraperitoneal injection of CsA into C57BL/6 mice, the brain, kidney, liver, spleen, and intestinal tissues were collected for MSI analysis. Our findings revealed increased accumulation of CsA and monohydroxy CsA in the renal cortex, liver, muscularis externa, and mucosa of the colon. CsA was found in higher amounts in the muscularis externa of the jejunum, whereas monohydroxy CsA was accumulated in the villus tips and penetrated the lumen of the treated mice. CsA was also detected throughout the spleen, but not monohydroxy CsA. The methodology demonstrated high precision (CV < 15%), establishing a robust analytical framework for utilizing AP-MALDI-MSI (iMScope QT) to evaluate the therapeutic efficacy and safety of CsA.
Indexed as
Identifiers
42026222What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.